Clinical trials: Controlled Human Infection
Chronic Hepatitis B
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only…
- Trial name
- NCT04423393
- Testing
- VIR-3434
- Where
- 24 sites in Germany, Hong Kong and 5 more
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Human Immunodeficiency Virus
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
The purpose of this study is to assess the safety and immunogenicity of M72/AS01E vaccination in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus infection (HIV).
- Trial name
- MESA-TB (NCT04556981)
- Testing
- M72/AS01E Mycobacterium tuberculosis vaccine
- Where
- 6 sites in South Africa
- Volunteers
- 402 people
- Sponsor
- Gates Medical Research Institute
Hepatitis C
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undetectable hepatitis C virus…
- Trial name
- NCT00704184
- Testing
- Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.
- Trial name
- NCT00877448
- Testing
- Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Critically Ill
Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients
Rationale: Enteral nutrition (EN) in the intensive care (ICU) patients is recommended as a standard of care. However, EN alone is often associated with insufficient energy intakes and increased complication rates.
- Trial name
- NCT00802503
- Testing
- SPN
- Where
- 2 sites in Switzerland
- Volunteers
- 305 people
- Sponsor
- University Hospital, Geneva
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
HIV-1 Infection
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency…
- Trial name
- NCT04564547
- Testing
- Islatravir, Ulonivirine, BIC/FTC/TAF
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh
This is a single center, multi-site, double-blind, parallel group, placebo-controlled trial of the clinical efficacy of trivalent Serum Institute of India, Ltd.
- Trial name
- NCT01797029
- Testing
- SIIL Live Attenuated Influenza Vaccine
- Where
- 2 sites in Bangladesh
- Volunteers
- 1,761 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
- Trial name
- NCT02677493
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Prefilled Syringe, IL-YANG Trivalent Influenza Vaccine
- Volunteers
- 1,794 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent…
- Trial name
- NCT01579916
- Testing
- Trivalent Influenza Virus Vaccine
- Where
- 3 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Hepatitis B Vaccine
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6 in methadone…
- Trial name
- NCT02991599
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 196 people
- Sponsor
- Shanxi Medical University
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604199
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Infection, Human Immunodeficiency Virus
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF).
- Trial name
- NCT01384734
- Testing
- BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 254 people
- Sponsor
- ViiV Healthcare
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
OPSCC N0 Nodal Control With Reduced IMRT
The dose of radiation most commonly used to treat oropharyngeal cancer results in side effects including sores in the mouth and throat, dry mouth and thick saliva, loss or altered taste, swallowing problems including pain or…
- Trial name
- NCT01891695
- Testing
- 39.6 Gy radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Paul W. Read, MD
Hepatitis C, Chronic
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with…
- Trial name
- NCT01440595
- Testing
- Grazoprevir, Peginterferon alfa-2b (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Hepatitis C
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral…
- Trial name
- FITNESS (NCT00987337)
- Testing
- Filibuvir
- Where
- 77 sites in United States, Belgium and 7 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Mosquito-Borne Disease
Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine
Background: Mosquitos carry diseases that cause major health problems and death worldwide. The AGS-v vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne diseases.
- Trial name
- NCT03055000
- Testing
- AGS-v, AGS-v + adjuvant
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Human Immunodeficiency Virus
A Single Dose of Pembrolizumab in HIV-Infected People
Background: Human immunodeficiency virus (HIV) attacks the immune system. Some people with HIV have a low CD4+ T-cell count despite taking antiviral medicines that control HIV replication.
- Trial name
- NCT03367754
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV Vaccination, Vaccine; Uptake
PREVENT HPV-Related Cancers - BootCamp Translation
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
- Trial name
- PREVENT (NCT06290206)
- Testing
- PREVENT - BCT
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Utah